| Quantitative characterization of in vitro bystander effect of antibody-drug conjugates AP Singh, S Sharma, DK Shah Journal of pharmacokinetics and pharmacodynamics 43, 567-582, 2016 | 121 | 2016 |
| Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model AP Singh, X Zheng, X Lin-Schmidt, W Chen, TJ Carpenter, A Zong, ... MAbs 12 (1), 1688616, 2020 | 91 | 2020 |
| Model‐based cellular kinetic analysis of chimeric antigen receptor‐T cells in humans C Liu, VS Ayyar, X Zheng, W Chen, S Zheng, H Mody, W Wang, D Heald, ... Clinical Pharmacology & Therapeutics 109 (3), 716-727, 2021 | 73 | 2021 |
| Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development AP Singh, YG Shin, DK Shah Pharmaceutical research 32, 3508-3525, 2015 | 63 | 2015 |
| Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation AP Singh, L Guo, A Verma, GGL Wong, GM Thurber, DK Shah The AAPS journal 22, 1-13, 2020 | 53 | 2020 |
| Application of a PK-PD modeling and simulation-based strategy for clinical translation of antibody-drug conjugates: a case study with trastuzumab emtansine (T-DM1) AP Singh, DK Shah The AAPS journal 19, 1054-1070, 2017 | 52 | 2017 |
| Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition AP Singh, W Krzyzanski, SW Martin, G Weber, A Betts, A Ahmad, ... The AAPS journal 17, 389-399, 2015 | 52 | 2015 |
| Evolution of antibody-drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (T-DM1) AP Singh, KF Maass, AM Betts, KD Wittrup, C Kulkarni, LE King, A Khot, ... The AAPS journal 18, 861-875, 2016 | 50 | 2016 |
| Measurement and mathematical characterization of cell-level pharmacokinetics of antibody-drug conjugates: a case study with trastuzumab-vc-MMAE AP Singh, DK Shah Drug Metabolism and Disposition 45 (11), 1120-1132, 2017 | 44 | 2017 |
| Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T AP Singh, W Chen, X Zheng, H Mody, TJ Carpenter, A Zong, DL Heald CPT: Pharmacometrics & Systems Pharmacology 10 (4), 362-376, 2021 | 35 | 2021 |
| A “dual” cell-level systems PK-PD model to characterize the bystander effect of ADC AP Singh, DK Shah Journal of pharmaceutical sciences 108 (7), 2465-2475, 2019 | 27 | 2019 |
| Evolution of the systems pharmacokinetics-pharmacodynamics model for antibody-drug conjugates to characterize tumor heterogeneity and in vivo bystander effect AP Singh, GM Seigel, L Guo, A Verma, GGL Wong, HP Cheng, DK Shah Journal of Pharmacology and Experimental Therapeutics 374 (1), 184-199, 2020 | 25 | 2020 |
| A cell-level systems PK-PD model to characterize in vivo efficacy of ADCs AP Singh, L Guo, A Verma, GGL Wong, DK Shah Pharmaceutics 11 (2), 98, 2019 | 19 | 2019 |
| From cold to hot: changing perceptions and future opportunities for quantitative systems pharmacology modeling in cancer immunotherapy V Lemaire, D Bassen, M Reed, R Song, S Khalili, YT Lien, L Huang, ... Clinical Pharmacology & Therapeutics 113 (5), 963-972, 2023 | 13 | 2023 |
| Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients AM Salem, GM Mugundu, AP Singh CPT: Pharmacometrics & Systems Pharmacology 12 (9), 1285-1304, 2023 | 7 | 2023 |
| Utility of PK-PD Modeling and simulation to improve decision making for antibody-drug conjugate development AP Singh, DK Shah Innovations for next-generation antibody-drug conjugates, 73-97, 2018 | 7 | 2018 |
| Dynamics of erythropoietic biomarkers in response to treatment with erythropoietin in Belgrade rats LM Nguyen, AP Singh, P Wiczling, W Krzyzanski Frontiers in Pharmacology 9, 316, 2018 | 6 | 2018 |
| Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice CH Tsai, AP Singh, CQ Xia, H Wang Journal of Pharmacokinetics and Pharmacodynamics 49 (5), 525-538, 2022 | 5 | 2022 |
| Evolution of the systems PK-PD model for antibody-drug conjugates (ADC) to characterize tumor heterogeneity and in vivo bystander effect AP Singh, GM Seigel, L Guo, A Verma, GGL Wong, HP Chang, DK Shah Journal of Pharmacology and Experimental Therapeutics, 2020 | 3 | 2020 |
| Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors. TE Nakajima, Y Kuboki, M Fukahori, Y Shimazu, S Kondo, Y Katsuya, ... Journal of Clinical Oncology 42 (16_suppl), 2543-2543, 2024 | 2 | 2024 |
